Morishige Naoyuki, Uemura Aiko, Morita Yukiko, Nishida Teruo
*Division of Cornea and Ocular Surface, Ohshima Eye Hospital, Fukuoka, Japan; and †Department of Ophthalmology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Cornea. 2017 Dec;36(12):1544-1548. doi: 10.1097/ICO.0000000000001344.
Topical application of the fibronectin-derived peptide PHSRN facilitates corneal epithelial wound healing in healthy animals and in patients with nonhealing epithelial defects. We have now examined the effect of PHSRN eye drops on the healing of corneal epithelial wounds in diabetic rats.
Wistar rats were injected intraperitoneally with streptozotocin to induce diabetes or with a vehicle as a control. Four weeks after confirmation of the corresponding presence or absence of glycosuria, a 3-mm-diameter portion of the corneal epithelium of the right eye was excised and eye drops containing PHSRN (200 μM) or phosphate-buffered saline (PBS) vehicle were administered to the injured eye every 6 hours.
The area of the epithelial defect did not differ significantly among the 4 experimental groups (diabetic or nondiabetic rats treated with PHSRN or vehicle) at 12 hours after wounding. At 18 hours, however, the area of the defect in diabetic rats treated with PHSRN (0.50 ± 0.34 mm) was significantly (P < 0.05) smaller than that in diabetic rats treated with PBS (1.06 ± 0.42 mm) and was similar to that in nondiabetic rats treated with PBS (0.60 ± 0.23 mm). The decrease in the size of the epithelial defect in diabetic rats treated with PHSRN was also found to be dependent on the dose of the peptide.
Administration of PHSRN significantly facilitated healing of corneal epithelial wounds in diabetic rats, which suggests that PHSRN eye drops warrant further investigation as a treatment option for patients with diabetic keratopathy.
纤连蛋白衍生肽PHSRN局部应用可促进健康动物和上皮缺损不愈合患者的角膜上皮伤口愈合。我们现在研究了PHSRN滴眼液对糖尿病大鼠角膜上皮伤口愈合的影响。
给Wistar大鼠腹腔注射链脲佐菌素诱导糖尿病，或注射赋形剂作为对照。在确认相应的是否存在糖尿四周后，切除右眼直径3毫米的角膜上皮部分，每6小时向受伤眼滴注含PHSRN（200μM）或磷酸盐缓冲盐水（PBS）赋形剂的滴眼液。
受伤后12小时，4个实验组（用PHSRN或赋形剂治疗的糖尿病或非糖尿病大鼠）的上皮缺损面积无显著差异。然而，在18小时时，用PHSRN治疗的糖尿病大鼠的缺损面积（0.50±0.34毫米）显著小于（P<0.05）用PBS治疗的糖尿病大鼠（1.06±0.42毫米），且与用PBS治疗的非糖尿病大鼠（0.60±0.23毫米）相似。还发现用PHSRN治疗的糖尿病大鼠上皮缺损大小的减小也取决于肽的剂量。
给予PHSRN可显著促进糖尿病大鼠角膜上皮伤口愈合，这表明PHSRN滴眼液作为糖尿病性角膜病患者的一种治疗选择值得进一步研究。
